Ranbaxy Laboratories expects to start supplying a low-cost version of anti-ulcer drug, sold under the brand Nexium by AstraZeneca to the British drugmaker, towards the end of 2011. The drugmaker had entered into an agreement three years ago to supply a cheap version of the drug to Astra-Zeneca starting May 2010, that could fetch $40-50 million in annual revenues for Ranbaxy. The supply has been delayed due to pending approvals from the American drug regulator as the medicine is to be sold by AstraZeneca in the US.crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.70 |
| Dr. Reddys Lab | 1220.00 |
| Cipla | 1232.60 |
| Zydus Lifesciences | 928.05 |
| Lupin | 2305.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: